THALES
Thales unveils FlytEDGE, a revolutionary connected cloud-based inflight entertainment system that will transform passenger engagement to the extraordinary. FlytEDGE is not like a traditional IFE system — with a sleek architecture, cutting-edge features, and unparalleled performance it enables airlines to stand out by bringing the ‘cool’ factor to each seat, offering fully-tailored passenger interactions:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240528532879/en/
(Photo: Thales)
- Live personalization for a journey filled with unique experiences
- Instantly stream favorites and never miss a beat, continue watching on all flights
- Immense volume of content to immerse passengers in a world of entertainment choices
Creating personalized experiences
Personalization is at the heart of FlytEDGE. Every passenger is one-of-a-kind and the system empowers airlines to recommend experiences tailored to each person's preferences. FlytEDGE is a true engagement platform offering boundless opportunities for connected and custom journeys. FlytEDGE delivers ‘just-for-you’ experiences never seen before. The system intelligently recommends content across domains, with an individually tailored and immersive entertainment experience.
Delivering the future of entertainment to each passenger
FlytEDGE is the IFEC industry’s first solution to feature edge caching. Passengers can now instantly stream their favorite entertainment using their personal video subscriptions and continue watching their favorite shows from the ground to the air and across flights.
Leveraging a state-of-the-art connected cloud architecture, the system breaks through barriers providing airlines with unparalleled flexibility to rapidly bring in any web-based service.
- Top game providers for interactive options that will captivate from take-off to touch down
- Video streamers that go beyond the blockbuster to bring infinite bingeable choices to passengers
With FlytEDGE airlines can integrate partners at the speed of consumer technology to create exhilarating experiences at the forefront of inflight entertainment.
Thales’ FlytEDGE solution features the best consumer technologies on the market. The system boasts cinematic 4K QLED HDR seatback displays to immerse passengers with over 1 billon vibrant colors and two Bluetooth® connections so passengers can pair their personal wireless devices. The system broadcasts the same user interface onboard for all devices- phones, tablets and seatback screens. With Thales’ Crystal Cabin® award-winning power solution delivering high-speed charging at each seat to any passenger device, everyone arrives at their destination recharged, entertained, and relaxed.
Value for airline customers
FlytEDGE features the Crystal Cabin® award-winning Onboard Data Center (ODC) with 96TB of storage to enable on-board edge caching, this solution reduces connectivity consumption and ensures bandwidth is available for other inflight services. No matter how many people watch the same content, each title streams once to the aircraft allowing passengers to instantly access endless entertainment.
The ODC takes the IFE system performance to new heights.
- Replaces the traditional multi-server network with an effective and compact blade architecture
- Simplifies upgradeability path with easy blade swaps
- Ensures the highest system availability
FlytEDGE goes beyond the hardware by redefining software and content updates to reduce cost and lead-time.
- Exceptional Efficiency – Remote operations with virtual labs for anywhere, anytime updates
- Superior Performance – Real-time system monitoring and automated maintenance tasks
- Scalable and Evolving – Continuous integration of new services for a system that is always growing at the speed of consumer technologies
FlytEDGE is already flying! We’re just at the beginning of what’s possible with a fully connected cloud platform. FlytEDGE’s game-changing features and intuitive functionality sets it light-years ahead of the competition. Bringing Thales’ FlytEDGE technology to the airline industry means an in-flight experience that is as eagerly awaited as the destination itself, and there’s so much more to look forward to. It is time to embrace the EDGE.
“At Thales we’re always at the forefront of innovation, investing in digital technologies, and working with our partners to redefine the inflight experience. We’re delighted to bring FlytEDGE’s state-of-the-art capabilities to our airline customers to create memorable and fully-tailored passenger interactions.” said Yannick Assouad, Executive Vice-President Avionics, Thales. “FlytEDGE is the first connected cloud-based IFE to introduce ground-breaking new experiences with a true engagement platform offering boundless opportunities for unique journeys. Stay tuned for more exciting news as the system is set to premier on a leading global airline.”
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies within three domains: Defence & Security, Aeronautics & Space, and Cybersecurity and Digital Identity. It develops products and solutions that help make the world safer, greener and more inclusive.
The Group invests close to €4 billion a year in Research & Development, particularly in key innovation areas such as AI, cybersecurity, quantum technologies, cloud technologies and 6G.
Thales has 81,000* employees in 68 countries. In 2023, the Group generated sales of €18.4 billion.
* These figures exclude the ground transportation business, which is being divested
PLEASE VISIT
Thales Group
Thales InFlyt Experience
X @Thalesgroup
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240528532879/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom